$EVFM
Evofem Biosciences, Inc. Stock $evfm

$evfm Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000161883522000110 Filed on May 10, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$4.251M	$1.105M
YoY Change	284.71%
Cost Of Revenue	$1.066M	$506.0K
YoY Change	110.67%
Gross Profit	$3.185M	$599.0K
YoY Change	431.72%
Gross Profit Margin	74.92%	54.21%
Selling, General & Admin	$21.72M	$38.21M
YoY Change	-43.15%	154.78%
% of Gross Profit	682.04%	6378.8%
Research & Development	$10.39M	$7.262M
YoY Change	43.09%	70.99%
% of Gross Profit	326.25%	1212.35%
Depreciation & Amortization	$265.0K	$200.0K
YoY Change	32.5%	185.71%
% of Gross Profit	8.32%	33.39%
Operating Expenses	$32.11M	$45.98M
YoY Change	-30.15%	138.92%
Operating Profit	-$28.93M	-$44.87M
YoY Change	-35.53%	133.17%
Interest Expense	$523.0K	$1.152M
YoY Change	-54.6%
% of Operating Profit
Other Income/Expense, Net	-$2.956M	-$1.280M
YoY Change	130.94%	-1406.12%
Pretax Income	-$31.89M	-$46.15M
YoY Change	-30.91%	141.05%
Income Tax	$3.000K	-$1.000K
% Of Pretax Income
Net Earnings	-$31.89M	-$46.15M
YoY Change	-30.91%	141.05%
Net Earnings / Revenue	-750.13%	-4176.56%
Basic Earnings Per Share	-$2.88	-$8.46
Diluted Earnings Per Share	-$2.88	-$8.46
COMMON SHARES
Basic Shares Outstanding	11.09M shares	5.456M shares
Diluted Shares Outstanding	11.09M shares	5.456M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.761M	$45.30M
YoY Change	-93.91%	335.58%
Cash & Equivalents	$2.761M	$45.32M
Short-Term Investments
Other Short-Term Assets	$8.797M	$23.10M
YoY Change	-61.92%	670.0%
Inventory	$7.161M	$8.990M
Prepaid Expenses
Receivables	$4.416M	$2.914M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$21.36M	$80.34M
YoY Change	-73.41%	485.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.518M	$5.614M
YoY Change	-1.71%	802.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.706M	$1.022M
YoY Change	164.77%	-2.11%
Total Long-Term Assets	$13.21M	$13.13M
YoY Change	0.62%	580.96%
TOTAL ASSETS
Total Short-Term Assets	$21.36M	$80.34M
Total Long-Term Assets	$13.21M	$13.13M
Total Assets	$34.57M	$93.46M
YoY Change	-63.01%	497.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$14.04M	$6.501M
YoY Change	115.98%	-8.69%
Accrued Expenses	$9.749M	$8.978M
YoY Change	8.59%	259.26%
Deferred Revenue
YoY Change
Short-Term Debt	$267.0K	$53.20M
YoY Change	-99.5%
Long-Term Debt Due	$113.8M
YoY Change
Total Short-Term Liabilities	$154.5M	$75.71M
YoY Change	104.04%	423.52%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$25.70M
YoY Change	-100.0%
Other Long-Term Liabilities	$4.059M	$5.700M
YoY Change	-28.79%	2750.0%
Total Long-Term Liabilities	$4.059M	$31.40M
YoY Change	-87.07%	15600.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$154.5M	$75.71M
Total Long-Term Liabilities	$4.059M	$31.40M
Total Liabilities	$158.5M	$107.1M
YoY Change	48.02%	632.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$892.6M	-$701.6M
YoY Change	27.22%	31.81%
Common Stock	$759.2M	$688.0M
YoY Change	10.35%	29.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$128.1M	-$13.64M
YoY Change
Total Liabilities & Shareholders Equity	$34.57M	$93.46M
YoY Change	-63.01%	497.4%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$31.89M	-$46.15M
YoY Change	-30.91%	141.05%
Depreciation, Depletion And Amortization	$265.0K	$200.0K
YoY Change	32.5%	185.71%
Cash From Operating Activities	-$20.92M	-$34.46M
YoY Change	-39.29%	131.63%
INVESTING ACTIVITIES
Capital Expenditures	$66.00K	$956.0K
YoY Change	-93.1%	906.32%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$250.0K
YoY Change	-100.0%	-96.38%
Cash From Investing Activities	-$66.00K	-$706.0K
YoY Change	-90.65%	-110.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$28.05M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$15.13M	$28.01M
YoY Change	-45.98%	1953.23%
NET CHANGE
Cash From Operating Activities	-$20.92M	-$34.46M
Cash From Investing Activities	-$66.00K	-$706.0K
Cash From Financing Activities	$15.13M	$28.01M
Net Change In Cash	-$5.856M	-$7.158M
YoY Change	-18.19%	8.29%
FREE CASH FLOW
Cash From Operating Activities	-$20.92M	-$34.46M
Capital Expenditures	$66.00K	$956.0K
Free Cash Flow	-$20.99M	-$35.41M
YoY Change	-40.74%	136.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001618835
CY2021Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2022Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2022Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-36754
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	EVOFEM BIOSCIENCES, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8527075
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	12400 High Bluff Drive
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 600
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
CY2022Q1	dei	City Area Code CityAreaCode	858
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	550-1900
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12713254	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2761000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7732000	USD
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	4171000	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	5056000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4416000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6449000	USD
CY2022Q1	evfm	Inventories Current InventoriesCurrent	5386000	USD
CY2021Q4	evfm	Inventories Current InventoriesCurrent	7674000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4626000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3229000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	21360000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	30140000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5518000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5774000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4987000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5395000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2706000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1203000	USD
CY2022Q1	us-gaap	Assets Assets	34571000	USD
CY2021Q4	us-gaap	Assets Assets	42512000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	14041000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10316000	USD
CY2022Q1	us-gaap	Notes Payable Current NotesPayableCurrent	267000	USD
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9749000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8370000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5123000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4653000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2218000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2332000	USD
CY2022Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	7842000	USD
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	202000	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1414000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2864000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	154474000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	137663000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4059000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4424000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	158533000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	142087000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0.0001
CY2022Q1	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-128100000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-104315000	USD
CY2022Q1	us-gaap	Revenues Revenues	4251000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34571000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1145000	USD
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12322049	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12322049	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10833308	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10833308	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	759197000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	751275000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5270000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5089000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-892568000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-860680000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42512000	USD
CY2021Q1	us-gaap	Revenues Revenues	1105000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1066000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	506000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10391000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7262000	USD
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	12705000	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	30525000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9018000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7684000	USD
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	33180000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	45977000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-28929000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-44872000	USD
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	7000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-471000	USD
CY2022Q1	evfm	Loss On Issuance Of Financial Instruments LossOnIssuanceOfFinancialInstruments	852000	USD
CY2021Q1	evfm	Loss On Issuance Of Financial Instruments LossOnIssuanceOfFinancialInstruments	0	USD
CY2022Q1	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-1634000	USD
CY2021Q1	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-142000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2956000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1280000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31885000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-46152000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-31888000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-46151000	USD
CY2022Q1	evfm	Temporary Equity Convertible Preferred Stock Deemed Dividends TemporaryEquityConvertiblePreferredStockDeemedDividends	81000	USD
CY2021Q1	evfm	Temporary Equity Convertible Preferred Stock Deemed Dividends TemporaryEquityConvertiblePreferredStockDeemedDividends	0	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-31969000	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-31969000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-46151000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-46151000	USD
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.88
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.88
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.46
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.46
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11092862	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11092862	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5456221	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5456221	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-31888000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-46151000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	181000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	0	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31707000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46151000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-31888000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-104315000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5400000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	708000	USD
CY2022Q1	evfm	Temporary Equity Convertible Preferred Stock Deemed Dividends TemporaryEquityConvertiblePreferredStockDeemedDividends	81000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	181000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	828000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1067000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-128100000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1347000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	27709000	USD
CY2021Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	7000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3464000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-46151000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-13638000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-31888000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-46151000	USD
CY2022Q1	evfm	Loss On Issuance Of Financial Instruments LossOnIssuanceOfFinancialInstruments	852000	USD
CY2021Q1	evfm	Loss On Issuance Of Financial Instruments LossOnIssuanceOfFinancialInstruments	0	USD
CY2022Q1	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-1634000	USD
CY2021Q1	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-142000	USD
CY2022Q1	evfm	Warrant Modification WarrantModification	828000	USD
CY2021Q1	evfm	Warrant Modification WarrantModification	0	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1067000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3464000	USD
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	265000	USD
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	195000	USD
CY2022Q1	us-gaap	Lease Cost LeaseCost	395000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	330000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	523000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	1152000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2033000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1847000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-755000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1676000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1036000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-13606000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3735000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4647000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-85000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4713000	USD
CY2022Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	469000	USD
CY2021Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3510000	USD
CY2022Q1	evfm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-466000	USD
CY2021Q1	evfm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-229000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20919000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34458000	USD
CY2022Q1	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	0	USD
CY2021Q1	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	66000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	956000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-66000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-706000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	10000000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	351000	USD
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	37000	USD
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	7000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15129000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28006000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5856000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7158000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13588000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72251000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7732000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65093000	USD
CY2022Q1	evfm	Deferred Offering Costs Included In Accounts Payable And Accrued Expense DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense	61000	USD
CY2021Q1	evfm	Deferred Offering Costs Included In Accounts Payable And Accrued Expense DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense	304000	USD
CY2022Q1	evfm	Receivable From Issuance Of Common Stock ReceivableFromIssuanceOfCommonStock	331000	USD
CY2021Q1	evfm	Receivable From Issuance Of Common Stock ReceivableFromIssuanceOfCommonStock	0	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	57000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	519000	USD
CY2022Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	644000	USD
CY2021Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2022Q1	evfm	Temporary Equity Value Exchange Of Convertible Securities TemporaryEquityValueExchangeOfConvertibleSecurities	1616000	USD
CY2021Q1	evfm	Temporary Equity Value Exchange Of Convertible Securities TemporaryEquityValueExchangeOfConvertibleSecurities	0	USD
CY2022Q1	evfm	Proceeds From Issuance Of Notes And Warrants ProceedsFromIssuanceOfNotesAndWarrants	10000000	USD
CY2022Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	5700000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	2800000	USD
CY2022Q1	evfm	Working Capital Surplus Deficit WorkingCapitalSurplusDeficit	-133100000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-892600000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the notes thereto.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ignificant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items, the trade accounts receivable credit loss reserve estimate, the discount rate used in estimating the fair value of the lease right</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use (ROU) assets and lease liabilities, the assumptions used in estimating the fair value of notes, derivative liabilities, warrants and purchase rights issued, the useful lives of property and equipment, the recoverability of long-lived assets, inventory reserves, clinical trial accruals, the assumptions used in estimating the fair value of stock-based compensation expense and in assessing the probability of achieving certain milestones associated with the performance-based restricted stock awards (performance-based RSAs). These assumptions are more fully described in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if4fda611da6c47bfbe4d89fbb91555ab_43" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3- Revenue</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if4fda611da6c47bfbe4d89fbb91555ab_49" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 4- Debt</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if4fda611da6c47bfbe4d89fbb91555ab_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 6- Fair Value of Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if4fda611da6c47bfbe4d89fbb91555ab_61" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7- Commitments and Contingencies</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if4fda611da6c47bfbe4d89fbb91555ab_70" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 9- Stock-based Compensation</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets, liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</span></div>
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances on amounts in excess of federally insured limits due to the financial position of the depository institutions in which these deposits are held.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the United States and consist of wholesale distributors, retail pharmacies, and a mail-order specialty pharmacy. The </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company extends credit to its customers in the normal course of business after evaluating their overall financial condition and evaluates the collectability of its accounts receivable by periodically reviewing the age of the receivables, the financial condition of its customers, and its past collection experience. Historically, the Company has not experienced any credit losses. As of March 31, 2022, based on the evaluation of these factors, the Company did not record an allowance for doubtful accounts. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phexxi is distributed primarily through three major distributors and a mail-order pharmacy, who receive service fees calculated as a percentage of the gross sales, and fee per units shipped, respectively. These entities are not obligated to purchase any set number of units and distribute Phexxi on demand as orders are received. For the three months ended March 31, 2022 and 2021, the Company’s three largest customers combined made up approximately 70% and 87% of its gross product sales, respectively. As of March 31, 2022 and December 31, 2021, the Company's three largest customers combined made up 73% and 75%, respectively, of its trade accounts receivable balance.</span></div>
CY2020Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	25000000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2761000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45318000	USD
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	4171000	USD
CY2021Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	18975000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7732000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65093000	USD
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9449211	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2785622	shares
CY2022Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1000400	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.88
CY2022Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1037885	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.1805
CY2022Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	574000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	574000	USD
CY2022Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1737000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1712000	USD
CY2022Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4850000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5629000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	7161000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	7915000	USD
CY2022Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	300000	USD
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	300000	USD
CY2022Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	1800000	USD
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	200000	USD
CY2022Q1	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	6549000	USD
CY2021Q4	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	5294000	USD
CY2022Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1972000	USD
CY2021Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1997000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8370000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	608000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	550000	USD
CY2022Q1	evfm	Accrued Manufacturing Related Costs Current AccruedManufacturingRelatedCostsCurrent	0	USD
CY2021Q4	evfm	Accrued Manufacturing Related Costs Current AccruedManufacturingRelatedCostsCurrent	201000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	620000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	328000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9749000	USD
CY2022Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	5121000	USD
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	11176000	USD
CY2022Q1	evfm	Lessee Operating Lease Number Of Vehicles Leased LesseeOperatingLeaseNumberOfVehiclesLeased	71	vehicle
CY2019Q4	evfm	Office Square Footage OfficeSquareFootage	24474	sqft
CY2019Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2020Q2	evfm	Office Square Footage OfficeSquareFootage	8816	sqft
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	576000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	593000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M17D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M29D
CY2022Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12
CY2021Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1818000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2160000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2192000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1502000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7672000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1395000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	6277000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	634000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	486000	USD
CY2022Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Purchases UnrecordedUnconditionalPurchaseObligationPurchases	0	USD
CY2021Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Purchases UnrecordedUnconditionalPurchaseObligationPurchases	1100000	USD
CY2022Q1	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
CY2022Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6556094	shares
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	16.34
CY2022Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6556094	shares
CY2022Q1	evfm	Common Stock Reserved Upon Exercise Of Common Stock Warrants CommonStockReservedUponExerciseOfCommonStockWarrants	6556094	shares
CY2022Q1	evfm	Common Stock Reserved For The Conversion Of Preferred Stock CommonStockReservedForTheConversionOfPreferredStock	892664	shares
CY2022Q1	evfm	Common Stock Reserved For The Conversion Of Convertible Notes CommonStockReservedForTheConversionOfConvertibleNotes	6256088	shares
CY2022Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	14961009	shares
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1067000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3464000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	217718	shares

Files In Submission

Name	View Source	Status
0001618835-22-000110-index-headers.html	Edgar Link	pending
0001618835-22-000110-index.html	Edgar Link	pending
0001618835-22-000110.txt	Edgar Link	pending
0001618835-22-000110-xbrl.zip	Edgar Link	pending
delawarestamp.jpg	Edgar Link	pending
evfm-20220331.htm	Edgar Link	pending
evfm-20220331.xsd	Edgar Link	pending
evfm-20220331_cal.xml	Edgar Link	unprocessable
evfm-20220331_def.xml	Edgar Link	unprocessable
evfm-20220331_htm.xml	Edgar Link	completed
evfm-20220331_lab.xml	Edgar Link	unprocessable
evfm-20220331_pre.xml	Edgar Link	unprocessable
evfm-3312022xex31.htm	Edgar Link	pending
evfm-3312022xex311.htm	Edgar Link	pending
evfm-3312022xex312.htm	Edgar Link	pending
evfm-3312022xex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stateofdelawarestamp.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EVFM
Evofem Biosciences, Inc. Stock $evfm

2022 Q1 Form 10-Q Financial Statement

#000161883522000110 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM Evofem Biosciences, Inc. Stock $evfm

2022 Q1 Form 10-Q Financial Statement

#000161883522000110 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM
Evofem Biosciences, Inc. Stock $evfm